Jaguar Health Q3 prescription revenue $3.1M (+412% YoY); net loss widens to $12.5M

Jaguar Health, Inc.

2022-Q3 EPS reported -$0.49

Prescription product net revenue $3.1M in Q3 2022, up 8.2% QoQ and 412% YoY vs $0.6M.
Net loss $12.5M ($0.12/sh) vs $12.2M loss in Q3 2021; operating loss $9.9M vs $9.5M.
R&D expense rose to $5.9M from $3.3M driven by Phase 3 crofelemer CTD trial.
OnTarget Phase 3 CTD trial targets enrollment completion in Q2 2023.
Non-GAAP EBITDA loss $8.5M, flat YoY; no guidance provided.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Jaguar Health, Inc. reported third quarter 2022 results: revenue approximately $3.1 million.

Period: third quarter 2022
Revenue: approximately $3.1 million
Result: reported results

Exact text from the filing

The combined net revenue for Mytesi ® and the Company’s other prescription product, Canalevia ® -CA1, which became commercially available in April 2022, was approximately $3.1 million in the third quarter of 2022, representing an increase of 8.2% over prescription product net revenue in the second quarter of 2022, which totaled approximately $2.9 million, and an increase of approximately 412% over Mytesi net revenue in the third quarter of 2021, which totaled approximately $0.6 million.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Jaguar Health, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-117760

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.